Document is current
Any future updates will be listed below
-
Authors
Al-Hasani, Wiaam https://orcid.org/0000-0002-4764-7755
Cheliotis-James, Thomas https://orcid.org/0009-0001-9212-6174
Wierzbicki, Anthony S. https://orcid.org/0000-0003-2756-372X
Freyberg, Zachary https://orcid.org/0000-0001-6460-0118
Howes, Oliver https://orcid.org/0000-0002-2928-1972
Pillinger, Toby https://orcid.org/0000-0002-6074-2626
- License Information
-
More Information
Article History
Received: 9 December 2025
Accepted: 5 March 2026
First Online: 20 April 2026
Competing interests
: Dr Freyberg reports investigator-initiated funding from UPMC Enterprises. Dr Howes reports investigator-initiated research funding from and/or participated in advisory or speaker meetings organised by AbbVie, Alkermes, Angelini, Autifony, Biogen, Boehringer Ingelheim, Delix, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Janssen, Karuna, Lundbeck (where he was previously a part-time employee), Merck, Neumora, Neurocrine, Ontrack/Pangea, Otsuka, Sunovion, Teva, Recordati, Roche, ROVI Biotech, Viatris, and Mylan. Dr Pillinger reports receiving speaker/consultancy fees from Boehringer Ingelheim, Bristol Myers Squibb, Recordati, Lundbeck, Otsuka, Janssen, CNX Therapeutics, Sunovion, Teva Pharmaceuticals, ROVI Biotech, Schwabe Pharma, and Lecturing Minds Stockholm AB; receiving book royalties from Wiley Blackwell; and co-directing a company that designs digital resources to support treatment of mental illness outside the submitted work. The remaining authors declare no conflicts of interest.
